BACKGROUND: Early treatment with valproic acid (VPA) has demonstrated benefit in preclinical models of traumatic brain injury, including smaller brain lesion size, decreased edema, reduced neurologic disability, and faster recovery. Mechanisms underlying these favorable outcomes are not fully understood. We hypothesized that VPA treatment would upregulate genes involved in cell survival and proliferation and downregulate those associated with cell death and the inflammatory response.
V alproic acid (VPA) has gained recent attention for use as a pharmacologic agent in trauma, and has undergone extensive preclinical testing in the setting of traumatic brain injury (TBI). 1, 2 After decades of use as a treatment for epilepsy, it was discovered that in higher doses it has action as a histone deacetylase inhibitor (HDACI). 3 Nuclear DNA is complexed with histones within chromatin-these histones are subject to posttranslational modifications, which affects their association with DNA. This is broadly controlled by two classes of enzymes; histone acetyltransferases (HATs), and histone deacetylases (HDACs). Inhibition of HDACs results in increased acetylation of histones, disrupting the association with DNA and causing relaxation of the chromatin structure. DNA is therefore made more accessible to transcriptional machinery, and gene transcription is upregulated.
An imbalance in HAT/HDAC activity has been shown in both hemorrhagic shock (HS) 4 and neurodegeneration, 5 which justifies the testing of VPA in this context. Our group has tested VPA treatment in various models of HS, 6 TBI, 7 and polytrauma, 2 and has shown significant improvement in outcomes. These positive studies have led to phase I clinical testing of VPA (NCT01951560). 8 The beneficial effects of VPA are largely attributed to its action as an HDACI, but the exact mechanisms are still not fully characterized.
Mechanistic studies have demonstrated differential regulation of master transcription factors by VPA and modulation of multiple pathways involved in the inflammatory response, cell survival, and neurogenesis. 9, 10 Our group and others have also shown prosurvival changes at the protein level. 6, 11, 12 The aim of this study was to define the transcriptomic changes induced by VPA in swine subjected to TBI and HS. RNA sequencing was performed on injured brain tissue to allow for characterization of the transcriptome and differential gene expression analysis. Our hypothesis was that VPA treatment would upregulate genes involved in cell survival and proliferation, and downregulate those that are associated with cell death and inflammation.
METHODS
All experiments adhered to guidelines stipulated in the Animal Welfare Act and all federal statutes regarding animal experiments. These experiments were approved by the Institutional Animal Care and Use Committee and performed under supervision of veterinarian staff.
Injury Model
Swine were subjected to a well-described model of TBI and HS. 13, 14 In brief, female Yorkshire swine (40-50 kg; Michigan State University, East Lansing, MI) were anesthetized and instrumented for hemodynamic and intracranial monitoring. Hemodynamic, intracranial, and laboratory parameters were collected throughout the experiment. Hemodynamic data were compared between groups using unpaired t tests with Holm-Sidak correction and laboratory parameters compared using t tests with Welch's correction. All statistical analyses for this study were performed using GraphPad Prism version 6.00 (GraphPad Software, San Diego, CA). Animals were placed in the prone position, and the head was secured in a stereotactic frame. A 20-mm craniotomy was made anterior to the bregma. Next, a computer-controlled cortical impact device (custom-madeUniversity of Michigan Medical Innovation Center; Ann Arbor, MI) was used to induce a TBI (15-mm cylindrical impactor, 4-m/s velocity, 100-ms dwell time, 12-mm impact depth). Concurrently, animals were subjected to 40% total blood volume hemorrhage and maintained in a state of hypovolemic shock (mean arterial pressure, 30-35 mm Hg) for 2 hours via titration of isoflurane. Resuscitation was delayed for 2 hours to simulate prolonged extrication in a prehospital setting.
Animals were then randomized to one of two groups: normal saline alone (NS) or NS + VPA (n = 5/cohort). All animals were resuscitated with NS (3Â hemorrhage volume, infused over 1 hour) at the end of the shock period. Animals assigned to the NS + VPA group received a single 150 mg/kg peripheral intravenous injection of VPA (concentration, 100 mg/mL; total volume infused, 55-67.5 mL) infused over 90 minutes, starting 1 hour into shock, before NS resuscitation, to simulate a bridge to definitive care. Following a 6-hour observation period, animals were euthanized, and tissues were collected for further analysis.
Lesion Size and Edema
The brain was harvested and sliced into 5-mm coronal sections, and images were obtained for the calculation of edema using ImageJ analysis software (National Institutes of Health, Bethesda, MD). The following formula was applied to calculate brain edema: brain edema = (volume of ipsilateral hemisphere/ volume of contralateral hemisphere − 1) Â 100%. 15 Sections were then stained with 2% 2,3,5-triphenyltetrazolium chloride (Sigma Chemical Co., St. Louis, MO) to detect viable tissue and further images were obtained for lesion size calculation using ImageJ software. Lesion sizes and edema were compared using unpaired t test with Welch's correction and are expressed as mean ± standard deviation.
Tissue Sampling and RNA Extraction
Brain tissue from the region inferior to the most injured site was flash frozen in liquid nitrogen and stored at −80°C for subsequent analysis. RNA preparation methods have been described previously by our laboratory. 9, 10 RNA extraction from the frozen specimens was conducted utilizing an RNeasy Mini Kit (Qiagen, Valencia, CA).
RNA Sequencing
RNA sequencing was performed by the DNA Sequencing Core. RNA quality was assessed using TapeStation (Agilent, Santa Clara, CA), and samples with an RNA Integrity Number (RIN) of 8 or greater were prepared using the Illumina TruSeq Stranded mRNA Library Prep kits (RS-122-2101 and RS-122-2102; Illumina, San Diego, CA) per manufacturer's protocols. For each sample, 0.1 μg to 0.3 μg of RNA was converted to messenger RNA (mRNA) using polyA purification methods. The mRNA was then fragmented and copied into first-strand complimentary DNA (cDNA) utilizing random primers and reverse transcriptase. Prime ends of cDNAwere then adenylated, and adapters ligated. For multiplexed sequencing, a unique six-nucleotide barcode was identified in each sample. Final products were purified and enriched by polymerase chain reaction (PCR, 12 cycles) for the construction of a final cDNA library. Final libraries were again assessed using TapeStation and quantitative PCR (KAPA library quantification kit for Illumina Sequencing platforms, KK4835; KAPA Biosystems, Wilmington, MA), per manufacturer's protocols. After pooling, samples were clustered on the cBot system (Illumina) and sequenced over three lanes on the HiSeq 4000 (Illumina) using paired-end 50-nucleotide reads.
Gene Set Enrichment, Pathway Analysis, and Network Analysis
Reads were aligned to a reference using STAR, 16 and multiple redundant methods for differential expression analysis were used by two independent researchers, including DESeq2 17 and CuffDiff2 18 in R Bioconductor, 19 and D-GEX 20 in Python. 21 Only the agreement between these programs was included in analysis. Based on a negative binomial data model, 17, 22 differentially expressed genes were selected based on a significance level corrected for multiple comparisons using a false discovery rate (FDR) with a stringent threshold FDR of 0.001 or less. To ensure data normalization and bias exclusion, conditional quantile normalization was applied, and genes with low-level expression were filtered out. MA plots were generated to visualize pairwise comparison of log 2 -fold change versus mRNA isoform abundance for each differentially expressed transcript, and the delineation of significantly (FDR ≤ 0.001) upregulated and downregulated genes. Gene symbol, disease involvement, and gene function data were obtained from both gene ontology (GO) 23 and the gene set enrichment analysis (GSEA) module in Ingenuity Pathway Analysis (IPA) software . 24 Data were curated by independent researchers who were blinded to each other's correction. Pathway analysis was performed using IPA with filters specific to central nervous system tissue. The pathway results were compared with the M30 epilepsy network, which has been suggested as a gene network target of VPA.
RESULTS
Animals in both groups demonstrated comparable degrees of shock and response to resuscitation in terms of heart rate, mean arterial pressure, cardiac output, and intracranial pressure There were no adverse events associated with treatment. Brain lesion sizes were significantly smaller in the NS + VPA group than the NS only group (mean lesion size, mm 3 : NS = 3107 ± 999 vs. NS + VPA = 1690 ± 121, p = 0.03). Similarly, ipsilateral brain edema was significantly reduced in the NS + VPA group (edema, %: NS = 32.5 ± 6.6 vs. NS + VPA = 13.9 ± 10.6, p = 0.01).
The IPA analysis revealed an inter-connected subnetwork of 257 significantly upregulated genes following NS + VPA treatment (Fig. 1) . Upregulated genes included master transcription factors involved in astrocyte programming into glial differentiation, including NEUROD1, ASCL1, and SOX1; members of the circadian CLOCK gene family; and genes which code for hormone receptors and growth-related transcription factors (e.g., NR3C1, EGR1), ion channels (e.g., SCN1A, SCN8A, CACNB2, KCNB1), neurotransmitter receptors (e.g., ADRGB2, CHRNB2, OPRK1), synaptic molecules (e.g., SNAP25, SV2B, CHGA), neurofilament and associated cytoskeletal molecules (e.g., INA, NEFL, NEFM, NEFM), mRNA splicing regulators (e.g., RBFOX1, CELF4), chromatin factors, histone acetyl-and methyl-transferases (e.g., ARID1A, EP300), and the neuronal progenitor complex.
Ingenuity Pathway Analysis also revealed a subnetwork of 156 genes which were significantly downregulated (Fig. 2) . These genes referred to angiogenic factors and macrophage scavengers (e.g., MSR1, THBS1), inflammatory molecules and chemokines (e.g., CXCR, IL1A), epithelial cell proliferation, endothelial chemotactic molecules (e.g., FGF7, SELE), oligodendrocyte proliferation and myelin molecules (e.g., OPALIN, SOX10), cell death and apoptotic factors (e.g., BAD, IAPP, SMARCA2, SMARCB1), and cell cycle regulators (e.g., CCNB1, CDC7).
Network-based GSEA using IPA was utilized to identify the top 5 functional associations amongst genes affected by VPA treatment ( Table 1) In addition, IPA identified VPA as the top upstream regulator of upregulated genes (p = 1.15E-22). The master transcriptional regulator NEUROD1 was also significantly represented ( p = 1.66E-32). Further, VPA was identified as the top upstream regulator of downregulated genes ( p = 1.32E-23).
Similar results were obtained using GO, showing upregulated gene transcripts associated with neurogenesis, neuronal differentiation, CNS development, and circadian regulation of gene expression (Table 2) , and downregulated genes demonstrating repression of those involved in immune function and inflammation, glial cell and leukocyte migration, epithelial cell proliferation, and behavioral attributes, such as locomotion and the defense response ( Table 3) .
The upregulated genes were compared with a known set of 320 genes involved in epilepsy, called the "M30 network." 25 Of the 257 genes in this set, 107 genes overlapped with the M30 network (Fig. 3) . These genes were associated with nervous system development ( p = 5.42E-06), action potentials ( p = 2.78E-05), trans-synaptic signaling ( p = 3.09E-05), synaptic signaling (p = 3.09E-05), and regulation of membrane potential ( p = 1.69E-04). The remaining 150 genes upregulated by VPA following TBI and HS were associated with nervous system development ( p = 6.79E-30), generation of neurons ( p = 2.21E-23), neurogenesis ( p = 6.21E-22), regulation of nervous system development ( p = 2.56E-10), and regulation of neurogenesis ( p = 3.03E-19).
DISCUSSION
In this study, we found that VPA upregulated genes are associated with neurogenesis, neurotransmission, and neuroregulation, while downregulating genes are associated with cell death and inflammation. These changes correlate with reduced brain lesion size and edema.
Differential expression analysis revealed a total of 257 genes selectively upregulated by VPA administration. Gene set enrichment analysis using both IPA and GO demonstrated a pattern of increased neuronal proliferation and differentiation, regulation over CNS morphology, and control of circadian rhythm. Ingenuity Pathway Analysis also demonstrated that these genes map into an interconnected subnetwork of genes expressed in the brain tissue. This revealed additional functions in combination, including control of neurotransmission and regulation of cytoskeletal stability. This implies overall trends in increased neurogenesis, regulation of neurotransmission, and cytoskeletal stability associated with VPA treatment.
These data suggest that VPA may upregulate the development of new neurons in the injured brain. Neurogenesis occurs in response to TBI, 26 mainly in the perilesional area. 27 This is thought to be a component of remodeling after injury, which contributes to functional recovery. 28 Valproic acid may therefore increase the rate of neurocognitive recovery by this mechanism, as seen in our longterm studies. 2, 7 Valproic acid also increased expression of genes involved in neurotransmission and regulation of synaptic functions. Neurotransmission is shown to be disordered following brain injury, which is associated with potentiation of the primary injury. 29 The fact that these changes correlate with decreased lesion sizes suggests that VPA may help restore normal functions.
Gene set enrichment analysis also suggested that VPA upregulates genes involved in the circadian rhythm. Traumatic brain injury is associated with acute dysregulation of circadian rhythm, and this has been suggested as a potential target for treatment. 30 Circadian rhythm and clock genes are connected with many cellular functions, including the cell cycle 31 and deregulation of cell cycle progression, which may result in cell death. 32 Thus, VPA may decrease cell death via modulation of clock genes. Differential expression analysis revealed a total of 156 genes downregulated by VPA. Gene set enrichment analysis using both IPA and GO demonstrated a pattern of decreased apoptosis, immune activation, leukocyte migration, glial cell proliferation, and proliferation and movement of endothelial cells. Overall, this suggested a phenotype of attenuated cell death and inflammation and decreased gliosis (responsible for post-injury scarring). Network mapping and functional analysis additionally showed decreased angiogenesis represented by these transcripts.
These data imply modulation of the immune response and inflammation by VPA treatment, which corroborates our previous work. 9 This may translate into attenuation of secondary brain injury and decreased brain lesion size and edema. Along with the downregulation of proapoptotic genes, this suggests that VPA treatment offers an element of neuroprotection. Downregulation of gliosis by VPA could also explain functional recovery seen in other models, 2, 7 by allowing for remodeling in the place of scarring. Interestingly, although angiogenesis is thought to be paired with neurogenesis in mediating remodeling, 33 this study shows downregulation of genes involved in angiogenesis with VPA treatment.
Our analysis also identified key mediators of VPA-induced transcriptomic changes. As anticipated, VPA was found to be the top regulator. In addition to this, VPAwas shown to induce master transcription factors including NEUROD1, as has been shown in other studies. 34 Overall, these findings indicate that VPA has both direct and downstream effects on gene regulation.
Valproic acid's effects on gene transcription were compared with its mechanism involved in the treatment of epilepsy. Gene susceptibility for epilepsy has been studied extensively, revealing a common set of involved genes, known as the M30 network. This network involves 320 genes which are under tight developmental control and are highly involved in neural processes and synaptic function. 25 This network is thought to be targeted by VPA.
Our study demonstrates that 107 of the genes upregulated by VPA are shared with the M30 network, such genes play key roles in neurogenesis and neurotransmission. In addition to this, a separate cohort of 150 genes was also upregulated. These are also involved in neurogenesis and neurotransmission and only strongly induced following TBI. 34 Overall, this suggests that VPA possesses baseline effects on the M30 network as well as additional effects in the setting of TBI and HS. While this study focuses on VPA's action as an HDACI, it is likely that its mechanism extends beyond that of simple acetylation of histones. Although a number of possible mechanisms and key mediators have been discovered within recent years, future research should continue to expand on these.
There are several limitations to this study. First, although swine are commonly used for human translation, they are an imperfect surrogate for humans. Second, our injury model is not representative of all forms of TBI. Third, we evaluated genetic changes at 6 hours following treatment. It is well known that transcriptional changes are dynamic and time-dependent; our findings represent a single time point along a continuum of cellular alterations following treatment. Finally, we did not use a VPA-only cohort, because this was a lethal model which required resuscitation. However, we attempted to isolate its effects by comparing the NS and NS + VPA groups. We also do not have gene expression data from a sham group, so it is unclear if the effects of VPA on gene expression are restorative or de novo. Additional studies are already underway to fill in many of these gaps.
In conclusion, this study demonstrates VPA's effects on the transcriptome in a clinically relevant large animal model of TBI and HS. Following injury, VPA upregulates genes associated with neurogenesis, neurotransmission, and neuroregulation, and downregulates genes associated with cell death and inflammation. Such changes may play a key role in VPA's benefit following injury. This study provides further explanation of VPA's effect in trauma; however, more work is required for a comprehensive understanding of its mechanism. 
